Glass fibers in veterinary injections turned a routine quality problem into a nationwide safety recall.
Quick Take
- American Regent, Inc. Animal Health recalled two lots of Adequan Canine and two lots of Adequan i.m.
- The company said testing found visible glass fiber material in internally retained samples.
- The recall covered product sold for dogs and horses, and it reached the consumer level.
- No adverse events had been reported to the company at the time of the recall notice.
What Was Recalled
American Regent, Inc. Animal Health issued a nationwide recall of two lots of Adequan Canine Injection and two lots of Adequan i.m. Injection on July 31, 2026. Adequan Canine is the dog product, while Adequan i.m. is the horse product. The recalled lots were 25011 and 3369 for dogs, and 24416 and 25265P for horses.
‘Glass Fibers’ Found Inside Dog and Horse Medications Prompt Urgent Nationwide Recall https://t.co/DwIWQV0OxB
— People Pets (@PEOPLEPets) August 7, 2026
The recall reached veterinarians, distributors, wholesalers, and pet owners. DVM360 reported that the affected lots were shipped across the United States at different times, which shows why the company moved fast once the problem surfaced. This was not a broad shutdown of every Adequan product. It was a lot-specific recall tied to a narrow set of vials.
Why The Company Pulled It
The FDA said the products were recalled because glass fibers were found during testing of internally retained samples. That detail matters. It means the problem came from the company’s own sample review, not from a public injury report.
The FDA also said injectable products with particulate matter can cause local irritation, swelling, inflammation, pain, infection, or abscesses.
That risk statement explains the logic of the recall. A foreign particle inside an injectable medicine can do damage even if no one has reported harm yet. In this case, the company said it had not received reports of adverse events related to the recalled lots as of the notice date. The action was preventive, not reactive to a known injury pattern.
Why This Kind Of Recall Hits Hard
Pet owners hear “glass fibers” and think of a broken vial or a careless manufacturing line. The public record does not give a full root-cause answer.
It does, however, show a familiar pharmaceutical playbook: isolate the lots, warn the field, and stop use before a small defect becomes a larger one. That approach favors caution over delay.
The distribution history also raises the stakes. According to DVM360, the recalled lots had already moved through online pharmacies, distributors, wholesalers, and veterinary practices.
Once a product travels that far, a recall becomes a race against inventory already sitting in clinics, shelves, and storage rooms. The faster those lots are identified, the fewer animals face possible exposure.
What Owners And Clinics Were Told To Do
The company told people not to use the affected products and to contact a veterinarian if an animal had a problem that might be linked to the recall.
It also directed distributors, retailers, veterinary hospitals, clinics, and other consignees to stop distribution and return or discard remaining inventory. That is standard recall language, but it carries real weight when the product is injectable.
For dog and horse owners, the practical point is simple: check the lot number before use and do not assume a familiar brand is automatically safe. For clinics, this recall is a reminder that sterile products live or die on fine details, from filling lines to final inspection. When a vial fails that test, the damage can start long before anyone sees a symptom.
